CEConversations: Recent Episodes
Creative Educational Concepts
Welcome to CEConversations, a clinical podcast presented by Creative Educational Concepts designed to improve clinician performance and optimize patient outcomes.
Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively impacts patients’ clinical outcomes and quality of life. These challenges necessitate an integrated, longitudinal management approach that encompasses the totality of the interprofessional, multidisciplinary team of clinicians in pediatric and adult care settings.
In this CEC Oncology live, case-based symposium, expert faculty will discuss key characteristics of clinical presentation and disease advancement over a lifespan; review patient and caregiver education needs on the integration of MEK inhibitors in the management of NF1-associated PNs; and explore the role of nurses in comprehensive care plans, including disease monitoring, treatment personalization, toxicity management, and transitioning care of patients with NF1 across their lifespan.
Learn More: https://www.ceconcepts.com/activity/save-the-date-mek-inhibitors-in-neurofibromatosis-type-1-nursing-contributions-to-nf1-pn-management/
| Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face difficulties translating novel and emerging clinical trial data into everyday practice, particularly in identifying candidates for mitogen-activated protein kinase inhibitors, managing adverse events, and coordinating multidisciplinary care. Limited experience with NF1 further contributes to gaps in long-term disease monitoring and personalized treatment planning. To close these gaps, clinicians must be equipped with practical, case-based strategies to improve early disease recognition, evidence-based management, and interprofessional collaboration that includes a team-based approach to address both clinical and psychosocial needs in the journey of patients with NF1. In this CE Concepts live symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans that reflect current clinical standards and support individualized, longitudinal management.
Learn More: https://www.ceconcepts.com/activity/the-mektrix-decoding-the-real-world-impact-of-therapeutic-advances-in-neurofibromatosis-type-1-associated-plexiform-neurofibroma-management-across-pediatric-and-adult-populations-2/
| Desmoid tumors (DTs) are rare, locally invasive neoplasms that present significant challenges due to their variable presentation, diagnostic delays, and the evolving therapeutic landscape. Oncology nurses and nurse practitioners often lack sufficient training in identifying early signs of DTs, understanding novel systemic therapies like tyrosine kinase and gamma-secretase inhibitors, and managing their distinct adverse event (AE) profiles. As frontline providers in symptom management and patient counseling, these clinicians urgently need education on evidence-based strategies for monitoring and mitigating treatment-related toxicities. Targeted learning will empower nursing professionals to improve patient safety, support adherence, and deliver comprehensive, individualized care across the DT treatment continuum. In this CE Concepts recorded symposium, expert faculty will guide learners to identify features and challenges of early diagnosis and treatment of DTs, evaluate the use of novel targeted therapies, and implement evidence-based strategies to monitor and manage AEs associated with systemic therapies for DTs to improve patient safety and adherence.
Learn More:https://www.ceconcepts.com/activity/desmoid-tumors-in-focus-early-recognition-evolving-therapies-and-nursing-led-care-strategies-2/
As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present to the emergency room with symptoms of adverse effects (AEs). While T-cell-retargeting therapies have revolutionized the treatment of hematological malignancies, they are also associated with symptoms of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, infection, and cardiotoxicity. While most cases of CRS and neurotoxicity are self-limiting and only require supportive care, some patients can progress to needing ICU care. To address these risks, EM clinicians require education on the relationship of MOAs of T-cell-directing therapies to potential AEs and improve their confidence and competence in diagnosing and treating CRS, neurotoxicity, and other toxicities associated with these agents in emergency settings. In this CE Concepts webcast, expert faculty will guide learners on how to best evaluate the effect of CAR T-cell and bispecific antibody therapies on the immune system in patients with cancer, utilize best practices for the diagnosis and management of patients receiving T-cell-directing therapies experiencing symptoms consistent with CRS, and Integrate best practices for diagnostic and management approaches for patients receiving T-cell-directing therapies experiencing AEs not consistent with CRS.
Learn More: https://www.ceconcepts.com/activity/emergency-care-of-patients-with-cancer-receiving-car-t-cell-and-bispecific-antibody-immunotherapies-experiencing-serious-adverse-events/
In this enduring CEC ONS Chapter installment, expert faculty will review emerging data on ADC use for HER2-neg MBC and share insights and strategies on the impact of AEs associated with ADC use and approaches to the management of AEs associated with ADCs in this patient population. To learn more: https://www.ceconcepts.com/activity/treating-metastatic-her2-negative-breast-cancer-oncology-nursing-approaches-to-improve-patient-quality-of-life/
In this CE Concepts Grand Rounds series, expert faculty will examine the evolving treatment landscape for advanced cervical cancer and discuss how they develop individualized treatment plans that apply current guideline recommendations, consider new treatment methods, and respect the unique needs of each patient. Find more details and collect credit here: https://www.ceconcepts.com/activity/advancing-cervical-cancer-care-navigating-new-therapies-guidelines-and-patient-centric-approaches-2/
In this CEC Oncology recorded, case-based symposium, expert faculty will discuss diagnosis and disease challenges over a person’s lifespan; explore the integration of MEK inhibitors in the management of NF1-associated PNs in pediatric patients; and consider comprehensive interprofessional care plans that include disease monitoring, toxicity management, and individualizing disease treatment across the patient’s lifespan. Request credit: https://www.ceconcepts.com/activity/mek-inhibitors-in-neurofibromatosis-type-1-latest-advances-and-real-world-applications-in-nf1-pn-management-2/
In this virtual CE Concepts Grand Rounds, expert faculty will discuss strategies to better integrate diagnostic and prognostic biomarkers for DLBCL, utilize an evidence-based approach for personalizing treatment for patients with R/R DLBCL, and identify and mitigate the impact of AEs associated with novel therapies used in the treatment of patients with R/R DLBCL. See more information and collect credit here>>
In this CE Concepts Grand Rounds podcast, expert faculty will explore the latest clinical trial data on novel treatment options for patients with resistant/recurrent (R/R) CLL/SLL, utilization of an evidence-based approach for personalizing treatment for patients with R/R MCL, and prioritization of patient adherence and active engagement through development of multidisciplinary frameworks to oversee and address adverse events. The faculty will also provide insight through case-based discussions. Learn more: https://www.ceconcepts.com/activity/advancements-in-the-management-of-relapsed-refractory-b-cell-malignancies-integrating-recent-data-into-practice-to-improve-outcomes-2/
Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging, and highlight the need for targeted therapies based on molecular and genetic profiling to enhance treatment efficacy and reduce treatment-related adverse events (TRAEs). The role of CD30 expression further complicates patient care, because its variable expression among PTCL subtypes prevents establishing a uniform treatment approach. Though randomized clinical trial data is limited, these data can help refine treatment protocols and reduce the risk of relapse by identifying patients who may benefit from maintenance therapies or alternative treatment approaches.
In this CEC Oncology recorded Grand Rounds, expert faculty will evaluate the efficacy and safety of first-line PTCL treatments; explore the diagnostic, prognostic, and therapeutic applications of CD30 expression in PTCL subtypes; and discuss strategies to expand collaborative learning and communication that can enhance clinician understanding and proficiency in making informed therapeutic decisions as a treatment team.
Learn More: https://www.ceconcepts.com/activity/all-hands-on-deck-a-focus-on-current-and-emerging-treatment-options-in-the-frontline-setting-for-peripheral-t-cell-lymphoma-2/
Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis) in MF. These clinicians and their interdisciplinary collaborative care team need a deeper understanding of JAKis in MF, guideline-recommended risk-stratification algorithms, molecular indicators of disease prognosis, clinical features of MF, symptom burden, the impact of adverse events on treatment adherence, and health disparities in MF.
In this CE Concepts recorded Grand Rounds, expert faculty will discuss assessing patients for MF therapy, integrating current and emerging data on JAKis in MF, developing individualized strategies to reduce treatment toxicity and enhance treatment adherence, and evaluating health disparities in MF. The faculty will also provide insight through case examples.
Learn More at: | https://www.ceconcepts.com/activity/all-hands-on-deck-utilizing-jak-inhibitors-in-myelofibrosis-care-evidence-timing-and-strategic-approaches/
The reduced incidence of cervical cancer over the past few decades was primarily due to robust screening guidelines and vaccinations. However, despite the proliferation of screening programs, the diagnosis of cervical cancer is associated with inefficiencies and inconsistencies and has not decreased cervical cancer incidence further over the past decade. Additionally, numerous health care disparities persist as unaddressed medical needs, particularly for individuals with marginalized sexualities and genders. An exciting array of new immunotherapy options are further emerging for patients with locally advanced, recurrent, or metastatic cervical cancer, with promising potential to heighten treatment effectiveness. It is imperative that clinicians and the multidisciplinary care team are appraised on these novel therapies and are conscious of health care disparities and unique patient needs.
In this CE Concepts recorded webcast, expert faculty will guide learners on the implementation of recommended, inclusive, and universal screening techniques and programs for cervical cancer. Faculty will also evaluate the latest efficacy and safety data in different settings for the treatment of cervical cancer as well as incorporate actionable strategies to address disparities and the unique health care of individuals with marginalized sexualities and genders related to cervical cancer screening.
Learn more: https://www.ceconcepts.com/activity/all-hands-on-deck-in-cervical-cancer-care-screening-treatment-and-equity-strategies-to-improve-patient-lives-2/
The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This webcast will focus on emerging trial data for antibody-drug conjugates (ADCs); sequence optimization, combinatorial therapy utilization, and identification of when and in which patients to use ADCs; and anticipation, recognition, and management of treatment-related adverse events (TRAEs) in patients with metastatic urothelial cancer (mUC). Join our expert faculty for this 60-minute activity designed to help clinicians stay abreast of emerging trial data and evolving treatment guidelines, as well as effectively manage agent-specific AEs, to optimize care for their patients with mUC.
Learn more: https://www.ceconcepts.com/activity/tailoring-patient-care-using-novel-agents-in-metastatic-urothelial-carcinoma-strategies-for-the-interprofessional-team/
Cytomegalovirus (CMV) remains a major concern in both solid organ transplantation (SOT) and hematopoietic stem cell transplant (HSCT), primarily due to challenges related to treatment selection and monitoring, management of drug-related adverse events, and resistant/refractory disease. To minimize the impact of CMV infection in patients with HSCTs or kidney transplants, the interdisciplinary care team managing these patients must have guidance on incorporating novel antiviral therapies into prevention and treatment schemas for CMV.
In this CME Outfitters recorded Grand Rounds series, expert faculty will emphasize the burden of CMV in kidney transplantation and HSCT, review the benefits and limitations of current antiviral agents, and discuss the role of novel antivirals (e.g., letermovir and maribavir) for managing CMV. Additionally, case studies will demonstrate how to integrate novel antivirals into clinical practice to improve quality of care and outcomes.
Learn more: | https://www.cmeoutfitters.com/activity/cytomegalovirus-in-stem-cell-and-kidney-transplant-overcoming-the-limitations-of-conventional-antiviral-therapy/
Patients with triple-negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients and results in treatment disparities. Antibody-drug conjugates (ADCs) are novel agents which may improve patient outcomes. However, clinicians cannot implement them into practice appropriately or may be hesitant to use them altogether.
In this Grand Rounds activity, a breast cancer expert will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).
Learn more: https://www.ceconcepts.com/activity/advancements-and-applications-of-antibody-drug-conjugates-in-her2-negative-breast-cancer/
Patients with triple-negative breast cancer (TNBC), and those with HR-positive/HER2-negative breast cancer after the development of endocrine resistance, have limited treatment options. Black women are diagnosed more often with TNBC and feel the lack of treatment options more acutely, leading to greater outcomes disparities. Antibody-drug conjugates (ADCs) are novel agents that may improve outcomes for patients. However, clinicians lack the ability to implement them into practice appropriately or may be hesitant to use them altogether. This 90-minute enduring activity is led by a panel of breast cancer experts who will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).
Learn more: https://www.ceconcepts.com/activity/transforming-metastatic-breast-cancer-management-harnessing-the-power-of-antibody-drug-conjugate-therapies-2/
Download the slides: https://www.ceconcepts.com/wp-content/uploads/2024/08/MM-140—ASCO—240606-1.pdf
Download the Transcript: https://www.ceconcepts.com/wp-content/uploads/2024/08/MMV-140-Transcript_FINAL.pdf
Patient prognosis for endometrial cancer (EC) is highly benefited by molecular profiling, and national and international guidelines robustly recommend its integration into practice. Characterization of DNA mismatch repair (MMR) status identifies clinically significant molecular subtypes. This information assists clinicians in creating treatment plans tailored to specific tumor phenotypes and individual needs, including those patients with advanced and recurrent EC. Despite ringing endorsements and clear clinical applications, however, molecular profiling remains underutilized due to logistical challenges and a lack of clinician confidence. It is imperative that clinicians, in collaboration with the multidisciplinary team (MDT), become knowledgeable about this exciting technique and utilize it to enhance treatment decisions for patients.
In this CE Concepts enduring webcast, expert faculty will guide learners through integration of appropriate, guideline-directed molecular profiling strategies in the EC risk assessment and treatment decision process. Faculty will also assess the latest efficacy and safety data for the treatment of EC with learners and develop guideline-concordant and patient-specific therapeutic plans for patients with newly diagnosed advanced or recurrent EC that incorporate MDT collaboration strategies.
Learn More: | https://www.ceconcepts.com/activity/navigating-new-waters-for-advanced-or-recurrent-endometrial-cancer-2/
Reducing barriers to adequate anticoagulation for patients with cancer improves outcomes for those with cancer-associated venous thromboembolisms (CA-VTEs). Advances in cancer treatments and the resulting improvements in patient survival have led to an increase in the number of patients with cancer who develop a VTE at some point during their treatment (around 15%). CA-VTE is associated with decreased survival, increased morbidity and hospitalization, and the potential delay or interruption of systemic anti-cancer therapy. During this series, our faculty will expand clinician knowledge of VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams.
In this 60-minute program, expert faculty will review CA-VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams. Clinicians can expect to gain valuable insight that will help them understand and overcome barriers to adequate anticoagulant therapy for patients with cancer.
This podcast focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies that promote equitable care and outcomes for all patients; evaluate the role of antibody-drug conjugates (ADCs) in TNBC; and discuss the rapidly evolving clinical practice guidelines, safety and efficacy data of novel therapies, and practical ADC management strategies to anticipate and mitigate adverse events. To claim credit, visit: https://www.ceconcepts.com/activity/actionable-strategies-in-community-oncology-to-achieve-equity-in-triple-negative-breast-cancer-3/
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/
This podcast reviews the etiology and epidemiology of obesity, as well as prominent unmet needs and barriers to treatment optimization as a means of providing foundational context for learners. Expert faculty will then lead attendees on an immersive, deep dive through the established paradigm and the preponderance of emerging data for novel weight-loss therapeutics, most notably the GLP-1 agonists and the GLP-1/GIP agonists. The session will conclude with a case-based segment, in which attendees will get to apply the principles they have learned to real-world clinical scenarios, address practical weight-loss challenges, and highlight the instrumental role of the primary care physician as a gatekeeper for the obesity management team. Request credit here: https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/
Supported through an independent educational grant from Lilly.
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/igan-ee-podcast
This activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics in IgAN, including an appraisal of consensus guidelines and regulatory updates. Finally, the session will conclude with a case-based segment wherein attendees will get to apply the principles they’ve learned to real-world clinical scenarios.
Supported through an independent educational grant from Travere.
This educational session will comprehensively evaluate the current state of the bladder cancer management paradigm and investigate the emergence of new data across the totality of the disease continuum, with a particular emphasis on evidence-based treatment sequencing and the role of antibody-drug conjugates (ADCs) in subsequent lines of therapy for advanced disease. To conclude the session, activity attendees will get to apply the therapeutic principles they’ve learned to real-world clinical scenarios which will focus on patient-centric treatment selection and sequencing, as well as recognition, mitigation, and management of treatment-related adverse events.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
Collect credit: https://www.ceconcepts.com/gu-cancer23-on-demand
This educational activity will meet nephrology nurses where they are and provide them with expert insights into CKD-aP prevalence, patient burden, therapeutic rationale, and pivotal principles for safely and effectively integrating novel treatments into practice. The role of the nurse as a premier patient-facing care provider will be emphasized throughout, and notable focus will be placed on CKD-aP symptom recognition, patient education, drug administration, and toxicity management.
Collect credit: https://www.ceconcepts.com/ckd-ch-podcast
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/navigating-ckd-podcast#group-tabs-node-course-default1
To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on patient quality of life, progression of CKD, and cardiovascular events. Erythropoietin-stimulating agents (ESAs) are associated with significant cardiovascular safety-related concerns, but the emergence of the oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may improve erythropoiesis without the undesirable downstream effects of ESAs. However, HIF-PHIs place in therapy has not yet been fully elucidated. Here, join the interprofessional team of Dr. Ajay Singh, Dr. Jane Davis, and Dr. Calvin Meaney as they explore an incisive review of current CKD-anemia treatment and diagnostic challenges, as well as the evidentiary base for HIF-PHI utilization in CKD-anemia that establishes context for the future of these agents. In conclusion, a practical discussion of real-world patient case scenarios will be presented, to provide learners with context of the multiple comorbidities, complexities, diagnostic challenges, and barriers to appropriate treatment of CKD-anemia.
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/hk-ch-podcast
Learning Objectives
- Appraise key mechanisms of potassium homeostasis and review patient-centric risk factors for hyperkalemia.
- Discuss the prevalence and clinical gravity of hyperkalemia, with emphasis on acute care challenges and the morbidity/mortality impact of suboptimal renin-angiotensin-aldosterone system inhibitor (RAASi) utilization in the chronic setting.
- Evaluate novel K+ binder (patiromer and sodium zirconium cyclosilicate [SZC]) pharmacology, safety and efficacy profiles, and differential clinical utility across the hyperkalemia treatment continuum.
- Examine evolving clinical trial data in support of patiromer and SZC for hyperkalemia management, with a particular focus on usage in acute care and in-hospital settings.
- Use a case-based approach to design treatment strategies using novel K+ binders that the interprofessional care team can employ to improve hyperkalemia outcomes in the hospital.
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/sitc22-podcast
This session will review the totality of emerging evidence for immune checkpoint inhibitors (ICIs) in the hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) management calculus. Faculty will highlight the paradigmatic change ICIs have achieved, emphasize key teaching points for real-world use, and evaluate adaptive clinical trial designs and study schemas being used to investigate ICI-based treatment regimens in HCC and BTC on a prospective basis.
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/iv-iron-expert-exchange-podcast
In this Expert Exchange-based format, activity attendees will be immersed in a lively discussion between key thought leaders in the world of HF. Expert discussion will include an exploration of clinical trial data for intravenous (IV) iron therapies in HF and recently-updated expert consensus HF management guidelines, with emphasis on the emerging role of IV iron on improved clinical endpoints in HFrEF. Key teaching points up for debate include the safety and efficacy profiles of next-generation IV iron products, established and emerging clinical trial data in HF, and a comparative analysis of currently-available IV iron products.
To receive up to 2.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/2022chest-podcast
This dynamic live symposium, led by top experts in the field of pulmonary medicine and NSCLC, will take attendees on a deep dive into the sentinel role of the pulmonologist in the NSCLC management paradigm, exploring adaptive mechanisms to optimize collaborative strategies in a patient centric manner.
Learning Objectives
- Review the sentinel placement of the pulmonologist in the management of NSCLC, including their principal role in diagnostics, disease staging, and molecular testing.
- Evaluate clinical and patient-value driven factors that may help inform nodule evaluation and diagnostic strategies for pulmonologists, thus ensuring “the right tissue in the right amount from the right place for the right patient.”
- Demonstrate knowledge of guideline recommendations and practical considerations for the use of EBUS-TNBA techniques by pulmonologists, emphasizing the fundamentals of safely and effectively obtaining adequate tissue for diagnosis and molecular characterization.
- Describe the evolving role of targeted therapy and immunotherapy in NSCLC and analyze currently FDA-approved therapeutics across the NSCLC disease continuum, highlighting the role of molecular testing for guiding treatment and individualizing patient care.
- Explore the established utility of next-generation sequencing (NGS) and discuss the potential for emerging “next-generation” biomarkers in the NSCLC management paradigm.
- Apply patient-centric, evidence-supported collaborative care strategies to real-world, case-based scenarios in order to elucidate the pivotal role of the pulmonologist on the multidisciplinary team across the NSCLC continuum of care.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from AstraZeneca.
Learning Objectives
- Review the epidemiology and clinical characteristics of HR+, HER2- early-breast cancer (EBC), and identify patients at an elevated risk of disease recurrence as a means of guiding treatment.
- Appraise the current treatment landscape in HR+, HER2- EBC, including the established and emerging evidentiary base for novel therapies in the adjuvant setting, expert consensus guidelines, and FDA-approved indications.
- Recognize treatment-related adverse events associated with oral therapies used in HR+, HER2- EBC and implement evidence-supported mitigation and management protocols.
- Using real-world patient case examples, design on-label treatment plans for HR+, HER2- EBC at high risk for recurrence, emphasizing the critical need for effective communication and coordination strategies among the multidisciplinary community-based breast cancer care team.
- Evaluate adaptive approaches for promoting adherence and persistence to oral anticancer therapies, highlighting common reasons for noncompliance and the impact of patient counseling and shared decision-making (SDM).
Presented by:
Hope S. Rugo, MD
Professor, Division of Hematology/Oncology
Director, Breast Oncology Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from Lilly.
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/ovarian-gr-podcast
Learning Objectives
- Review recent updates to national guideline recommendations in ovarian cancer treatment and testing and discuss health equity issues that may hinder ovarian cancer patients from receiving the current standard of care.
- Appraise landmark and emerging safety and efficacy data with PARP inhibitors in the treatment of ovarian cancer, with a focus on most recent recommendations and rationale for the use of PARP inhibitors in the first-line maintenance setting.
- Analyze the unique toxicity profiles among PARP inhibitor therapies and important considerations for both monitoring and managing adverse events.
- Use an interactive, multi-disciplinary approach to discuss challenging cases regarding the appropriate selection of treatment based on clinical data and guidelines, the use of predictive biomarkers, the management of adverse events, and strategies to mitigate modifiable healthcare disparities in ovarian cancer patients.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from GSK.
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/iv-gr-podcast#group-tabs-node-course-default1 Learning Objectives
- Review the clinical gravity and foundational pathophysiology of iron deficiency anemia (IDA) in pediatric patients, with an emphasis on patient impact and the need for treatment.
- Evaluate the evolving clinical trial evidentiary base for intravenous (IV) iron as IDA management in pediatric patients, including a summary of recent FDA approvals and updated label indications for IV iron therapies.
- Discuss practical aspects of IV iron usage in the pediatric setting, including appropriate dosing, safety considerations, and clinician adherence to evidence-based IDA treatment standards.
- Use a real-world, case-based format to design evidence-supported strategies for recognizing, diagnosing, treating, and evaluating IDA in pediatric patients, focusing on the interpolation of IV iron into the management paradigm.
Presented By:
Jacquelyn M. Powers, MD, MS
Assistant Professor of Pediatrics
Associate Chief, Pediatric Hematology
Baylor College of Medicine
Texas Children's Cancer and Hematology Centers
Houston, TX
Learning Objectives
- Review the formative facets of iron absorption and metabolism, including the practical distinctions between functional and absolute iron deficiency, with expert analysis of how these principles dictate treatment approaches.
- Summarize the multifactorial etiologies and complex pathophysiology of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA), emphasizing the implications of CRA/CIA on oncologic outcomes and patient-centric metrics.
- Appraise completed, ongoing, and planned clinical trials of IV iron products in CRA/CIA, highlighting the established ability of these agents to enhance hematopoietic response rates, decrease transfusion burden, and improve patient outcomes.
- Discuss how next-generation IV iron products have dramatically improved upon the safety profiles of earlier generation agents, particularly with respect to severe hypersensitivity reactions.
- Review current expert consensus guidelines for CRA/CIA management from ASCO/ASH, NCCN, and ESMO.
- Use real-world patient cases to evaluate evidence-supported strategies that members of the multidisciplinary and interprofessional cancer care team can use to safely and effectively implement IV iron into clinical practice.
- Compare and contrast the unique clinical utility of currently-approved IV iron agents, emphasizing the impact of differential safety profiles on treatment decisions.
- Investigate the clinical implications of IV iron-associated hypophosphatemia in all patients, but especially in those with cancer and/or those actively receiving chemotherapy.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from Pharmacosmos Therapeutics, Inc.
Join our Expert Faculty, Drs. Joel W. Neal, MD, PhD and Victoria Sherry, DNP, CRNP, AOCNP as they discuss treatment principles across the continuum of care in unresectable, stage III NSCLC. During their presentations and discussion, they will examine the established treatment landscape for unresectable, stage III NSCLC as well as the emerging role of immunotherapy, and practical clinical considerations for anticipating, mitigating, and managing immune-related adverse events.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from AstraZeneca.
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/cras-enduring#group-tabs-node-course-default3
All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies. The vicious cycle of cardiorenal anemia syndrome (CRAS)—the pathologic triad wherein the three conditions are each capable of causing and/or being caused by the other—can be effectively mitigated and managed with IV iron. Unfortunately, clinician hesitancy in prescribing IV iron, largely due to adverse effects associated with earlier formulations, must be overcome before the full benefit of IV iron in CRAS can be realized. Join Drs. Matthew Weir and Javed Butler as they address CRAS pathophysiology, examine applicable expert consensus guidelines, and review current evidence for treatment. Practical, case-based elements will be offered that provide learners with real-world examples of IV iron safety, efficacy, and the need for multidisciplinary (nephrologist-cardiologist-PCP) care.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from American Regent.
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://ce.ceconcepts.com/EGFR1
This Rapid Recap will provide a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting, and offer expert insights into the shifting management landscape for metastatic EGFR+ NSCLC. These data will be placed in context of the established paradigm, with key scientific messages and pivotal points highlighted for audience takeaway. The session will conclude with a patient-led roundtable evaluating the multifarious burden of financial toxicity on optimal and equitable outcomes in NSCLC.
Supported through an independent educational grant from EQRx International, Inc.
Presented by Creative Educational Concepts, LLC.
To receive up to 1.0 CME/CE credits please complete the evaluation and request form here: https://ce.ceconcepts.com/GILGRPOD Learning Objectives
- Discuss the multifaceted etiology of the racial disparity observed in triple-negative breast cancer (TNBC), with a focus on both biologic and non-biologic factors, and identify tangible strategies community-based clinicians can employ to promote equitable care and outcomes for all patients.
- Review antibody-drug conjugate (ADC) structure, mechanism of action, and real-world clinical considerations, including dosing, administration, and toxicity management, for community oncology clinicians using ADCs to manage TNBC.
- Examine completed, ongoing, and planned clinical trial data for ADCs as part of the evolving and expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.
- Using a patient case-driven approach, design evidence-based treatment plans for patients with TNBC, with an emphasis on the placement of novel therapies in the shifting TNBC treatment calculus and the effective integration of socioeconomic and other non-biologic factors into equitable cancer care.
*Supported by independent educational grant from Gilead.
Presented by Creative Educational Concepts, LLC.*
To receive up to 1.5 ANCC contact hours, please complete the evaluation and request form here: https://ce.ceconcepts.com/ONS2022
This symposium will explore the latest ovarian cancer guideline recommendations and recent evidence for PARP inhibitors in treatment and maintenance settings. The nurse’s role in facilitating access to quality care for those with disparities, the unique toxicity profiles of PARP inhibitors, and how to mitigate, anticipate, and manage toxicities that may arise will also be discussed. Attendees will interact with the expert faculty through patient cases with audience response questions incorporated throughout.
Supported through an independent educational grant from GlaxoSmithKline.
Presented by Creative Educational Concepts, LLC.
Visit this link to complete the CE request form & evaluation: https://www.surveymonkey.com/r/NFCZ38X
This activity will review the failure rates of traditional therapies for DLBCL, such as R-CHOP, and evaluate patient-centric factors that contribute to disease progression and/or relapse. Expert faculty will then guide attendees through an evidence-based examination of the exigent need for more effective front-line therapeutic options in DLBCL, emphasizing practical clinical pearls and notable distinguishing features of novel and emerging treatment agents and their potential to optimize patient outcomes.
Supported by an independent educational grant from Genentech.
Visit this link to take the Post-Test Evaluation: https://www.ceconcepts.com/22-HFGR-PodcastThis activity will review how social determinants of health have led to inequities and disparate outcomes in HF. Attendees will take part in an expert-led exploration of current treatment guidelines, with an emphasis on HFrEF, and a review of emerging novel therapeutics. Learners will review real-world cases, empowering them to effectively interpolate novel agents into established guideline-directed medical therapy (GDMT) protocols and promote the closure of outcomes chasms driven by disparities in care.
Supported by an independent educational grant from Merck.
Click here to take the Pre & Post Test: https://ce.ceconcepts.com/AR22ONCMM
This Medical Moments webinar will review all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA). The activity will begin with a brief primer on iron metabolism and absorption principles, including the practical distinctions between absolute and functional iron deficiency, and the impact of that distinction on treatment approaches. An appraisal of the foundational pathophysiology of CRA will follow, with a central emphasis on the role of hepcidin in a hyperinflammatory disease state like cancer, and the resultant rationale for the preferential use of intravenous (IV) iron versus oral iron modalities in patients with cancer. Finally, the preeminent emphasis of the session will be an incisive exploration of completed, ongoing, and planned clinical trials of IV iron for CRA/CIA, including systematic reviews and meta-analyses, as well as recently-reported pivotal trials, such as IRON-CLAD.
Supported through an independent educational grant from American Regent.
Our hosts interview two pharmacists, both of whom have expertise in the realms of vaccine supply chain management, distribution, and administration, regarding the myriad challenges and practical hurdles posed by a global pandemic - and key strategies to overcome them.
Guests:
Joel Thornbury, President, Kentucky Pharmacists Association (KPhA); Owner, Nova Pharmacy;
Brooke Hudspeth, PharmD, Associate Professor and Chief Practice Officer, University of Kentucky College of Pharmacy
Our hosts interview an immunology researcher and vaccine expert regarding how effectively harnessing the immune system possesses the power to defeat the pandemic and restore normalcy to the world.
Practical issues, such as the role of health inequities and social determinants of health, and how/when we can safely travel the world or simply eat at the restaurant down the street, are also addressed.
Guest:
Vincent Venditto, PhD
Assistant Professor
University of Kentucky College of Pharmacy
An infectious disease pharmacist and an immunology specialty pharmacist discuss current and emerging data about COVID-19 with a renowned virologist. They review where we've been, the current state of affairs as the vaccine supply chain is stretched to capacity on an international scale, and perhaps most importantly--where we can expect to be in 6 months.
Episode Guest: Rebecca Dutch, PhD (Hosts: Craig Martin, PharmD, MBA; Dave Feola, PharmD, PhD)